Reducing parenteral support: patient and healthcare professional preferences for potential new short bowel syndrome therapies

Document Type

Conference Proceeding

Publication Date

10-1-2025

Publication Title

Clin Nutr ESPEN

Abstract

Rationale: Understanding patient and healthcare provider (HCP) preferences for treatment and outcome attributes in patients with short bowel syndrome (SBS) dependent on parenteral support (PS) can inform management strategies and therapeutic advancements. Methods: A noninterventional, cross-sectional, online survey evaluating potential new treatment and outcome attributes was conducted in the US and Europe in patients with SBS on parenteral support (≥18 years at diagnosis) and HCPs with ≥2 years of SBS experience managing ≥1 patient. Results: Responses were collected from 91 patients and 336 HCPs. Patients’ mean age was 50.4 years (58.2% female; 69.1% White). Patients were on total parenteral nutrition (TPN; 90.1%) and or IV hydration (73.6%) and glucagon-like peptide-2 analog therapy (24.2%); 42.3% of HCPs were physicians. Among patients, outcome attributes rated as very important included minimizing TPN (70.3%), IV hydration nutrition (64.8%), and side effects (68.1%). Most (67.0%) considered a days week TPN decrease meaningful, including a 1–2 days week decrease (33.0%). 63.3% rated minimizing injection frequency as very important. For HCPs, among attributes rated as very important, top priorities were reducing TPN central venous access need related risks (73.5%), hospitalizations (72.8%), and injection frequency (63.4%). Reducing TPN was meaningful to 95.8% of HCPs, including a 1–2 days week decrease (44.3%). Conclusion: Patients highly rated reducing TPN dependence associated risks, with even a 1 day week TPN reduction considered meaningful, and decreasing injection frequency for potential new SBS therapies. HCPs valued reducing central venous access need related risks, hospitalizations, and injection frequency. These findings highlight critical unmet needs in SBS management and the importance of therapies that reduce PS burden and side effects, leading to improved patient outcomes. Disclosure of Interest: S.-M. Jafri Consultant for: Intercept, Ironwood, AbbVie, Gilead, Takeda, and Ipsen, J. Harrison Other: Volunteer for Girls With Guts, V. Kumpf Consultant for: Ironwood, Baxter Healthcare, and Fresenius Kabi, G. Mitchell Other: Employee of Ironwood and may hold shares and or stock options in the company., D. Wolin Other: Full-time employee of RTI Health Solutions, an independent nonprofit research organization, which was retained by Ironwood to conduct the research that is the subject of this abstract. Their compensation is unconnected to the studies on which they work., L. Zografos Other: Full-time employee of RTI Health Solutions, an independent nonprofit research organization, which was retained by Ironwood to conduct the research that is the subject of this abstract. Their compensation is unconnected to the studies on which they work., M. Yang Other: Employee of Ironwood and may hold shares and or stock options in the company., L. Jackson Other: Full-time employee of RTI Health Solutions, an independent nonprofit research organization, which was retained by Ironwood to conduct the research that is the subject of this abstract. Their compensation is unconnected to the studies on which they work., J. Wang Other: Full-time employee of RTI Health Solutions, an independent nonprofit research organization, which was retained by Ironwood to conduct the research that is the subject of this abstract. Their compensation is unconnected to the studies on which they work., J. Henderson Other: Employee of Ironwood and may hold shares and or stock options in the company., M. Boules Other: Employee of Ironwood and may hold shares and or stock options in the company., R. Vemulapalli Other: CME Faculty for Novus Medical Education

Volume

69

First Page

898

Last Page

899

Find It @ Sladen

Share

COinS